{"news_desk": "Editorial", "print_page": "30", "subsection_name": null, "section_name": "Opinion", "byline": {"original": "By THE EDITORIAL BOARD", "person": [], "organization": "THE EDITORIAL BOARD"}, "abstract": "Editorial rebukes Congress for merely censuring Mylan's chief executive for significantly raising price of EpiPens instead of directly addressing issue of rising drug costs; calls for empowering Medicare to negotiate prices with drug makers and making it easier for generic drug makers to bring cheaper version to market.", "type_of_material": "Editorial", "word_count": "526", "keywords": [{"rank": "1", "value": "Drugs (Pharmaceuticals)", "is_major": "Y", "name": "subject"}, {"rank": "2", "value": "Epinephrine (Drug)", "is_major": "Y", "name": "subject"}, {"rank": "3", "value": "Prices (Fares, Fees and Rates)", "is_major": "N", "name": "subject"}, {"rank": "4", "value": "Generic Brands and Products", "is_major": "Y", "name": "subject"}, {"rank": "5", "value": "Inventions and Patents", "is_major": "N", "name": "subject"}, {"rank": "6", "value": "Lobbying and Lobbyists", "is_major": "N", "name": "subject"}, {"rank": "7", "value": "Mylan Inc", "is_major": "Y", "name": "organizations"}, {"rank": "8", "value": "Antitrust Laws and Competition Issues", "is_major": "N", "name": "subject"}, {"rank": "9", "value": "Medicare", "is_major": "Y", "name": "subject"}, {"rank": "10", "value": "Editorials", "is_major": "Y", "name": "subject"}], "lead_paragraph": "It\u2019s time for Congress to stop letting pharmaceutical companies get away with price gouging on lifesaving drugs.", "pub_date": "2016-09-22T04:00:00+0000", "document_type": "article", "source": "The New York Times", "snippet": "It\u2019s time for Congress to stop letting pharmaceutical companies get away with price gouging on lifesaving drugs....", "multimedia": [{"height": 126, "subtype": "wide", "legacy": {"widewidth": "190", "wide": "images/2016/09/22/opinion/22thu2/22thu2-thumbWide.jpg", "wideheight": "126"}, "type": "image", "width": 190, "url": "images/2016/09/22/opinion/22thu2/22thu2-thumbWide.jpg"}, {"height": 600, "subtype": "xlarge", "legacy": {"xlargewidth": "600", "xlargeheight": "600", "xlarge": "images/2016/09/22/opinion/22thu2/22thu2-articleLarge.jpg"}, "type": "image", "width": 600, "url": "images/2016/09/22/opinion/22thu2/22thu2-articleLarge.jpg"}, {"height": 75, "subtype": "thumbnail", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2016/09/22/opinion/22thu2/22thu2-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "url": "images/2016/09/22/opinion/22thu2/22thu2-thumbStandard.jpg"}], "web_url": "http://www.nytimes.com/2016/09/22/opinion/the-epipen-outrage-continues.html", "slideshow_credits": null, "blog": [], "_id": "57e32b7995d0e021d7987a0a", "headline": {"main": "The EpiPen Outrage Continues", "content_kicker": "Editorial", "print_headline": "The EpiPen Outrage Continues", "kicker": "Editorial"}}